Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.87 |
| ▸ | AR | P10275 | 2/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | SHBG | P04278 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10380855 | 1.00 | PGR (0.87) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL10380853 | 1.00 | PGR (0.87) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL11432808 | 0.94 | PGR (0.83) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL11438892 | 0.93 | PGR (0.85) | PGRARCHRM1HIF1ALMNA | |
| Hydrocortisone Aceponate SCHEMBL3697 | 0.93 | PGR (1.00) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL4285504 | 0.92 | PGR (0.88) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL17219849 | 0.92 | PGR (0.80) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL4285507 | 0.92 | PGR (0.88) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL604267 | 0.92 | PGR (0.80) | PGRARCHRM1HIF1ALMNA | |
| SCHEMBL321463 | 0.91 | NR3C2 (0.84) | PGRARCHRM1HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106572970-B | Novel gel for topical administration of non-steroidal anti-inflammatory drugs for relief of musculoskeletal pain and method of making same | 詹姆斯·布兰查德 | 2021-04-06 | — | — | CN | claimed |
| WO-2015191402-A1 | NOVEL GEL FOR TOPICAL DELIVERY OF NSAIDS TO PROVIDE RELIEF OF MUSCULOSKELETAL PAIN AND METHODS FOR ITS PREPARATION | BLANCHARD JAMES (US) | 2015-12-17 | — | — | WO | claimed |
| US-9012402-B1 | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation | BLANCHARD JAMES (US) | 2015-04-21 | — | — | US | claimed |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240189237-A1 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | WATERSHED MEDICAL INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240156720-A1 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-05-16 | — | — | US | disclosed |
| US-20240139133-A1 | TOPICAL NAPROXEN FORMULATIONS AND THEIR USE | SMARTECH TOPICAL, INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4333826-A1 | TOPICAL NAPROXEN FORMULATIONS AND THEIR USE | Smartech Topical, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240050362-A1 | TRANSDERMAL DELIVERY FORMULATIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-02-15 | — | — | US | disclosed |
| WO-2001043775-A2 | HYDROXIDE-RELEASING AGENTS AS SKIN PERMEATION ENHANCERS | DERMATRENDS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-0153001-B1 | STEROIDS HAVING AN ENAMIDE OR ENIMIDE GROUP AND THEIR PREPARATION | THE UPJOHN COMPANY (US) | 1992-03-11 | — | — | EP | disclosed |
| US-4831131-A | 11β,17α-Dihydroxy-17β-cyano-androstanes | THE UPJOHN COMPANY (US) | 1989-05-16 | — | — | US | disclosed |
| US-4585590-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4548748-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0153001-A2 | Steroids having an enamide or enimide group and their preparation | THE UPJOHN COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4500461-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-02-19 | — | — | US | disclosed |
| US-4036831-A | Trimethyl siloxane steroid intermediates | STEROID DEVELOPMENT COMPANY ESTABLISHMENT (CH) | 1977-07-19 | — | — | US | disclosed |
| US-3956349-A | TRIETHYL ORTHOACETATE, ACID CATALYST | SYNTEX (U.S.A.) INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, PLAT | PGR 754/4885AR 3322/4885CHRM1 2623/4885 |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, MMP2 | PGR 1064/4885AR 3870/4885CHRM1 3462/4885 |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | IL6, FLT4, TEK | PGR 2333/4885AR 4016/4885CHRM1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.